3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
8
Fallopian Tube Neoplasms
6
Breast Neoplasms
5
Sarcoma
3
Ovarian Cancer Recurrent
3
Carcinoma, Ovarian Epithelial
3
Sarcoma, Ewing
2
Neoplasm Metastasis
2
Leiomyosarcoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Vaccinia
1
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Low Grade Serous Ovarian Cancer
1
Liposarcoma
1
Hodgkin Disease
1
Histiocytoma, Malignant Fibrous
1
HER2-negative Breast Cancer
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Dermatofibrosarcoma
1
Interventions
pembrolizumab
2
lenvatinib
2
aldesleukin
2
Paclitaxel
2
Cisplatin
2
Carboplatin
2
Adoptive Transfer
2
trastuzumab deruxtecan
1
liposomal doxorubicin
1
fludarabine
1
dostarlimab
1
belzutifan
1
Vaccines, Synthetic
1
Therapeutic Touch
1
Taxes
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Standard of Care
1
Specimen Handling
1
Radiation
1
Practice Guidelines as Topic
1
Platinum
1
Papillomavirus Vaccines
1
Nivolumab
1
Nelfinavir
1
Imiquimod
1
Hysterectomy
1
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
1
Heavy Ion Radiotherapy
1
Gemcitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Vulvar Neoplasms
×
liposomal doxorubicin
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled